Immunic is committed to support all our patients participating in clinical trials. We are currently reviewing the fluid situation in Ukraine, but want to support you to have access to your study medication.
If you require support, please send us your Patient Number in your clinical study and the site (location) where you were originally enrolled. If possible, please do not provide us with your full name or other personal information.
If you are an ongoing study participant from Ukraine and have relocated, please contact the following mobile numbers via WhatsApp, Viber or Telegram for further information regarding potentially continuing your study participation:
|
Patients With Multiple Sclerosis: |
Patients With Ulcerative Colitis: |
|
Germany: +49 163 173 5556 |
Central contact: +49 172 630 49 21 |
IR Contact
Immunic, Inc.
1200 Avenue of the Americas, Suite 200
New York, NY 10036, USA
+1 332 2559811
info@imux.com
Media and Investor Inquiries
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
Rx Communications
Paula Schwartz
Managing Director
+1 917 322 2216
immunic@rxir.com